Gut microbiota is critical for the induction of chemotherapy-induced painOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
The researchers studied whether gut microbiota contributes to chemotherapy-induced pain. Chemotherapy-induced pain limits dosing and affects about 30% of patients undergoing treatment.
How was it studied?
Mice were treated with the chemotherapy drug oxaliplatin and tested for mechanical hyperalgesia. Germ-free mice and antibiotic-pretreated mice were compared to conventional mice, and microbiota restoration experiments were also performed.
What did they find?
Oxaliplatin-induced mechanical hyperalgesia was reduced in germ-free mice and in mice pretreated with antibiotics. Restoring the microbiota of germ-free mice abolished this protective effect. The effect appeared to be mediated in part by TLR4 expressed on hematopoietic cells, including macrophages.
Why it matters
The findings suggest gut microbiota is a driver of chemotherapy-induced pain rather than a bystander. This points to microbiota or TLR4 signaling as potential targets for reducing dose-limiting chemotherapy pain.